Abata Therapeutics

Associate Director, Clinical Outsourcing

Remote

Not SpecifiedCompensation
Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, Pharmaceuticals, HealthcareIndustries

Requirements

The Associate Director, Clinical Outsourcing should possess a Bachelor's degree and have at least 7 years of experience in clinical outsourcing, vendor management, or a related field. Strong negotiation skills and experience with contract management are essential, along with the ability to manage budgets and drive effective vendor selection and oversight. Familiarity with clinical trial operations and a solid understanding of outsourcing strategies are also required.

Responsibilities

The Associate Director, Clinical Outsourcing will lead outsourcing and vendor management at a program level, fostering long-term relationships with vendors and collaborating with clinical operations leads. They will manage the contract lifecycle, create partnerships with vendors, develop scope of work documents, and actively negotiate rates with CROs to ensure fiscal responsibility. This role involves assessing risk, developing contracts, communicating with internal and external stakeholders, overseeing vendor performance, and negotiating Clinical Trial Agreements (CTAs) and Site Budgets with institutions in the United States and Canada, as well as tracking investigator grant budgets across all clinical programs.

Skills

Vendor Management
Contract Negotiation
Budget Management
Clinical Outsourcing
Vendor Governance
RFI/RFP Process
Stakeholder Support

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Key Metrics

Cambridge, MassachusettsHeadquarters
2021Year Founded
$184.8MTotal Funding
EARLY_VCCompany Stage
BiotechnologyIndustries
11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.
Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.
Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.
Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.
Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.
FDA's accelerated approval pathways may expedite Abata's clinical trials.
Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI